Dickinson Andrew D, CFO, reported an open-market or private sale at GILEAD SCIENCES, INC. involving 137676.000000 shares for an estimated $14073240.72. Reported holdings after the transaction were 171223.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Financial Officer
The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
0 other filings
0 recent txs